Merck KGaA (MRK) Given a €100.00 Price Target by Warburg Research Analysts

Merck KGaA (FRA:MRK) has been assigned a €100.00 ($116.28) price target by equities research analysts at Warburg Research in a note issued to investors on Tuesday. The brokerage currently has a “neutral” rating on the healthcare company’s stock. Warburg Research’s price target would suggest a potential upside of 12.26% from the company’s previous close.

Several other equities research analysts also recently weighed in on MRK. Barclays set a €70.00 ($81.40) target price on shares of Merck KGaA and gave the company a “sell” rating in a research note on Friday, August 24th. Sanford C. Bernstein set a €105.00 ($122.09) target price on shares of Merck KGaA and gave the company a “buy” rating in a research note on Tuesday, July 3rd. Berenberg Bank set a €102.00 ($118.60) target price on shares of Merck KGaA and gave the company a “buy” rating in a research note on Thursday, August 30th. Goldman Sachs Group set a €92.00 ($106.98) target price on shares of Merck KGaA and gave the company a “neutral” rating in a research note on Wednesday, September 12th. Finally, Societe Generale set a €92.00 ($106.98) target price on shares of Merck KGaA and gave the company a “neutral” rating in a research note on Friday, August 10th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and nine have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of €98.81 ($114.89).

MRK stock traded up €0.70 ($0.81) during trading on Tuesday, hitting €89.08 ($103.58). 293,900 shares of the company’s stock traded hands. Merck KGaA has a 1 year low of €76.60 ($89.07) and a 1 year high of €115.00 ($133.72).

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Featured Article: Treasury Bonds

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply